Press Releases

ISA106 - SLP therapeutic for COVID-19

January 11, 2021
Interview with ISA Pharmaceuticals' CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cel...
Read more
ISA106 - SLP therapeutic for COVID-19

Macrophage Pharma expands Executive team with CSO and CTO

January 09, 2021
Key hires enhance management for next development phase
Read more
Macrophage Pharma expands Executive team with CSO and CTO

Klinische Fase 1a studie met lead compound INT-1B3

January 07, 2021
December 2020: Net voor Kerst in de bijlage van Het Algemeen Dagblad - InteRNA heeft klinische Fase 1a studie met lead compound...
Read more
Klinische Fase 1a studie met lead compound INT-1B3

Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

January 07, 2021
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer
Read more
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

January 06, 2021
• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 • Evaluation of Cristal's CliCr® and I...
Read more
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

December 17, 2020
Appointment of Björn Cochlovius, Ph.D. as Chairman of the Board
Read more
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

Sapreme Appoints Miriam Bujny as Chief Development Officer

October 27, 2020
Appointment of Miriam Bujny, Ph.D., as Chief Development Officer
Read more
Sapreme Appoints Miriam Bujny as Chief Development Officer

Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients

October 15, 2020
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients
Read more
Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients

Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

September 30, 2020
positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the O...
Read more
Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

September 29, 2020
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform, comprising a new class of sup...
Read more
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

Home > Press Releases

© 2021 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds